Sun Pharma, SPARC collaborate for commercialization of phenobarbital for injection in US
SPARC's phenobarbital sodium powder for injection is a benzyl alcohol and propylene glycol-free formulation intended for the treatment of seizures in neonates.
Mumbai: Sun Pharma, including its subsidiaries, and Sun Pharma Advanced Research Company Ltd. (SPARC) have announced the signing of a licensing agreement for the commercialization of benzyl alcohol and propylene glycol-free phenobarbital sodium powder for injection in the United States.
SPARC submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (US FDA) for this product for the treatment of neonatal seizures in February 2022. Currently, there are no phenobarbital injection products approved by the US FDA for the treatment of seizures in newborns.
Under the terms of the license agreement, Sun Pharma will pay SPARC an upfront payment of US $10 million. SPARC will also be eligible to receive milestone payments contingent upon the achievement of regulatory and sales milestones, as well as tiered royalties on sales.
"SPARC's benzyl alcohol and propylene glycol-free formulation of phenobarbital for injection is an exciting addition to our growing portfolio of specialty branded products in the U.S. Through our existing relationships with hospitals and other institutional customers, we are well-positioned to bring this product to market and make a difference in the lives of patients," said Abhay Gandhi, CEO North America, Sun Pharma.
"SPARC is excited to enter into this collaboration with Sun Pharma and is committed to developing new products to address the needs of patients. SPARC's benzyl alcohol and propylene glycol-free formulation of phenobarbital for injection is designed to minimize the risk of the neonatal gasping syndrome, a life-threatening condition, which can be observed with the use of benzyl alcohol-containing drug formulations," said Anil Raghavan, CEO, SPARC.
It was granted orphan drug designation by the US FDA for the treatment of neonatal seizures. The currently marketed phenobarbital formulations are notified under the DESI (Drug Efficacy Study Implementation) program list by the U.S. Department of Health and Human Services.
Read also: Sun Pharma Gets CDSCO Panel Nod To Study Elagolix tablet
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.